Ovatax

New Data Demonstrates Effectiveness of Clarient’s Ovatax™ Test for Ovarian Cancer.

See study, titled “Expression of TLE3 Predicts Response to Taxane Therapy in Ovarian Carcinoma,” included 293 carcinoma samples mostly collected at UAB

press release: Clarient Receives Patents for Taxane Biomarker - TLE3 (gene)

Note: Transducin-like enhancer protein 3 is a protein that in humans is encoded by the TLE3 gene

"Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United Kingdom Patent Office has granted a U.K. patent on the Company's TLE3 biomarker, a marker which may be used to predict which cancer patients will respond favorably to taxane therapy. In addition, the Company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent on the TLE3 biomarker. Other patents for the TLE3 biomarker are pending in the U.S., Canada, Japan, China, India and elsewhere in Europe.

The U.S. patent will cover uses of the TLE3 biomarker in breast cancer. The U.K. patent covers uses of TLE3 in breast, lung and ovarian cancers.
Taxanes are important cancer therapeutics which, in combination with other cancer therapies, can markedly improve a patient's response rate to therapy. However, taxanes also carry with them a significant incidence of severe side effects, making it important to identify which patients will most likely benefit from the therapy.

"Given the frequent prescription of taxanes in the U.S., the U.K. and elsewhere in Europe and the world, we are very excited about the granting of these patents and the protection they provide our taxane sensitivity marker," said Clarient Vice Chairman and CEO Ron Andrews."

press release: New Data Indicate Effectiveness of Clarient's Ovotax(TM) Test for Ovarian Cancer "TLE3"

The study summary and results may be found at http://www.clarientinc.com/Ovotax

ALISO VIEJO, Calif., March 17 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study shows that Clarient's Ovotax™ assay may effectively predict which ovarian cancer patients will respond favorably to taxane therapy and could, therefore, be spared the potential side effects of this rigorous and sometimes toxic chemotherapy agent. The study was presented yesterday at the national meeting on Women's Cancer of the Society of Gynecologic Oncologists by Janelle Fauci, M.D. of the Department of Obstetrics and Gynecology at the University of Alabama, Birmingham (UAB).

The study, titled "Expression of TLE3 Predicts Response to Taxane Therapy in Ovarian Carcinoma," included 293 carcinoma samples. Ovotax is a single antibody immunohistochemistry test created to detect the expression of TLE3 in an ovarian tumor and thereby indicate whether the patient will respond favorably to taxane therapy.